Deep in the wall of the duodenum, at the tiny junction where the bile duct and pancreatic duct empty into the small intestine, sits a structure barely larger than a fingernail tip: the ampulla of Vater. Tumors arising from the hormone-producing cells of this anatomical crossroads are among the rarest neoplasms in gastroenterology, and for decades clinicians have had little more than scattered case reports to guide them. Now a systematic review published in BMC Endocrine Disorders has pooled 14 years of published experience into the most detailed composite portrait yet of ampullary neuroendocrine tumors, offering data-driven answers to questions that individual clinicians rarely see often enough to answer themselves.
The research team, led by Lei Chen and WeiXia Du of the Department of Gastroenterology at Huanggang Central Hospital in Hubei Province, China, systematically searched the literature for studies on ampullary neuroendocrine tumors published between January 2010 and June 2024. From that search, 16 studies involving 32 patients met inclusion criteria. The investigators collected clinical and pathological data, imaging findings, treatment regimens, and follow-up outcomes, then retrospectively analyzed the pooled dataset. Because these tumors are so uncommon that no single center can accumulate a meaningful series, such pooled case-level analysis is one of the few ways to extract statistically meaningful patterns from the literature.
The demographic picture that emerges is consistent with what fragmentary prior reports suggested. Of the 32 patients, 19 were male and 13 female, a male-to-female ratio of 1.46 to 1, and the median age at diagnosis was 56 years, with patients ranging from 18 to 77. What makes the clinical picture treacherous, however, is how nonspecific it is. The most common presenting complaint was abdominal pain, seen in 35.5 percent of cases, followed by jaundice in 22.5 percent. Perhaps most strikingly, more than a quarter of cases, 25.8 percent, were discovered incidentally during routine health examinations, meaning a substantial fraction of patients had no symptoms at all pointing toward the ampulla.
That nonspecificity has real consequences. Ampullary neuroendocrine tumors are prone to being overlooked or misdiagnosed, the authors note, because their symptoms overlap with far more common conditions such as biliary colic, peptic ulcer disease, or ordinary ampullary adenomas. A patient with intermittent abdominal pain or mild jaundice may cycle through evaluations for gallstones before anyone considers a hormone-producing neoplasm hiding at the papilla. The review underscores that clinicians need a low threshold for examining the ampulla directly, particularly during endoscopic procedures performed for unrelated reasons, since incidental detection is already a common route to diagnosis.
On the imaging side, computed tomography dominated the diagnostic workup, having been used in 90.6 percent of cases, while magnetic resonance imaging was employed in 37.5 percent. But the headline finding of the review concerns tissue diagnosis rather than imaging. Endoscopic ultrasound-guided biopsy and endoscopic retrograde cholangiopancreatography-guided biopsy each achieved a diagnostic accuracy of 100 percent in the pooled cases. In an era when preoperative misdiagnosis remains a persistent problem for ampullary lesions generally, the message is unambiguous: when these endoscopic sampling techniques are deployed, they essentially never fail to establish the correct diagnosis before surgery.
The technical explanation for that accuracy lies in the anatomy and the tools. Endoscopic ultrasound places a high-frequency transducer directly adjacent to the ampulla through the duodenal lumen, allowing not only needle biopsy of the lesion but also precise measurement of tumor size and depth of invasion into the duodenal wall. ERCP, meanwhile, provides direct visual and contrast-based access to the ampullary orifice, permitting forceps biopsy from the exposed tumor surface. The review found the median tumor diameter to be just 15.5 millimeters, underscoring how small these lesions typically are at detection, and how critical high-resolution endoscopic assessment is for lesions that CT alone may characterize poorly.
Two pathological variables emerged as the key predictors of spread. Both larger tumor size and greater depth of invasion were associated with a higher rate of lymph node metastasis, and the authors additionally identified tumor grade as a factor linked to nodal risk. This trio of characteristics, size, depth, and grade, forms the practical decision tree for treatment planning. Small, superficial, low-grade tumors carry a low risk of occult nodal disease and can be candidates for organ-preserving local therapy, whereas larger, deeply invading, or higher-grade lesions demand more aggressive management because the probability that cancer has already reached regional lymph nodes rises substantially.
Treatment in the pooled cohort reflected that stratification. Endoscopic resection was performed in 31.3 percent of patients, while surgical resection accounted for 59.4 percent. Endoscopic resection, typically performed with techniques such as endoscopic papillectomy, spares the patient a major operation but is appropriate only for carefully selected early-stage cases confined to the superficial layers of the ampulla. Radical surgery, most commonly pancreaticoduodenectomy, remains the core therapeutic modality for high-risk or advanced-stage disease, removing the tumor together with regional lymph nodes. The authors emphasize that treatment decisions should be individualized according to tumor size, depth, and grade, and made through multidisciplinary collaboration among gastroenterologists, surgeons, pathologists, and oncologists.
The prognostic news is genuinely encouraging. With a median follow-up duration of 38.9 months, the pooled cohort showed a 5-year overall survival rate of 96.4 percent, a figure that stands in sharp contrast to the far grimmer outcomes of ampullary adenocarcinomas and neuroendocrine carcinomas. Well-differentiated neuroendocrine tumors of the ampulla, detected while still small, are in most cases indolent and curable. Yet the authors caution that the risk of recurrence persists even after apparently curative treatment, and they argue that establishing a long-term, regular follow-up system is crucial, especially for patients with high-risk pathological features such as larger size, deeper invasion, or higher grade.
The review’s authors are candid about the limits of their evidence. With only 32 patients drawn from retrospective published cases, the correlations they report between tumor characteristics and lymph node metastasis need to be verified in larger-scale prospective studies before they can harden into firm guidelines. Still, the analysis delivers practical takeaways that clinicians can apply immediately: consider ampullary neuroendocrine tumors in the differential of unexplained abdominal pain or jaundice, exploit EUS and ERCP-guided biopsy for near-certain preoperative diagnosis, let size, depth, and grade drive the choice between endoscopic resection and radical surgery, and commit every patient to structured long-term surveillance. For a tumor so rare that most physicians will see only a handful of cases in a career, 14 years of pooled global experience is a meaningful step from anecdote toward evidence.
Subject of Research: Clinical characteristics, diagnosis, treatment, and prognosis of ampullary neuroendocrine tumors
Article Title: Systematic review of ampullary neuroendocrine tumors: a pooled analysis of 32 cases reported from 2010 to 2024
Article References: Chen, L., Du, W., Fang, L., Wu, J., & Wang, C. (2026). Systematic review of ampullary neuroendocrine tumors: a pooled analysis of 32 cases reported from 2010 to 2024. BMC Endocrine Disorders. https://doi.org/10.1186/s12902-026-02460-2
Image Credits: AI Generated
DOI: 10.1186/s12902-026-02460-2
Keywords: ampullary neuroendocrine tumors, ampulla of Vater, systematic review, endoscopic ultrasound, ERCP, endoscopic resection, lymph node metastasis, neuroendocrine neoplasms, prognosis, gastroenterology, BMC Endocrine Disorders, pooled analysis
News Source: Ophelia Keating. (October 12, 2026). Rare Ampullary Neuroendocrine Tumors Yield Their Secrets in 14-Year Global Case Review. Scienmag.
